CN114058587A - hPSCs诱导分化制备的基底前脑胆碱能类器官及其制备方法 - Google Patents
hPSCs诱导分化制备的基底前脑胆碱能类器官及其制备方法 Download PDFInfo
- Publication number
- CN114058587A CN114058587A CN202111369833.1A CN202111369833A CN114058587A CN 114058587 A CN114058587 A CN 114058587A CN 202111369833 A CN202111369833 A CN 202111369833A CN 114058587 A CN114058587 A CN 114058587A
- Authority
- CN
- China
- Prior art keywords
- day
- differentiation
- culture
- cholinergic
- basal forebrain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004069 differentiation Effects 0.000 title claims abstract description 70
- 210000002220 organoid Anatomy 0.000 title claims abstract description 39
- 210000004129 prosencephalon Anatomy 0.000 title claims abstract description 35
- 230000001713 cholinergic effect Effects 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 210000004027 cell Anatomy 0.000 claims abstract description 44
- 230000001537 neural effect Effects 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 19
- 210000002242 embryoid body Anatomy 0.000 claims abstract description 18
- 210000002932 cholinergic neuron Anatomy 0.000 claims abstract description 11
- 238000012258 culturing Methods 0.000 claims abstract description 11
- 239000002609 medium Substances 0.000 claims abstract description 8
- 238000004115 adherent culture Methods 0.000 claims abstract description 6
- 230000003203 everyday effect Effects 0.000 claims abstract description 5
- 239000001963 growth medium Substances 0.000 claims abstract description 5
- 239000002243 precursor Substances 0.000 claims abstract description 4
- 230000001464 adherent effect Effects 0.000 claims abstract description 3
- 230000002062 proliferating effect Effects 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 24
- 230000006698 induction Effects 0.000 claims description 15
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 12
- 238000007664 blowing Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 238000004114 suspension culture Methods 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 7
- 108010007093 dispase Proteins 0.000 claims description 6
- 239000012091 fetal bovine serum Substances 0.000 claims description 5
- 210000005036 nerve Anatomy 0.000 claims description 4
- 102100023995 Beta-nerve growth factor Human genes 0.000 claims description 3
- 101710129634 Beta-nerve growth factor Proteins 0.000 claims description 3
- 102100035140 Vitronectin Human genes 0.000 claims description 3
- 108010031318 Vitronectin Proteins 0.000 claims description 3
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 239000007640 basal medium Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000005096 rolling process Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 6
- 239000011259 mixed solution Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 3
- 239000000725 suspension Substances 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 241000283074 Equus asinus Species 0.000 description 3
- 101150111110 NKX2-1 gene Proteins 0.000 description 3
- 230000004641 brain development Effects 0.000 description 3
- 238000001506 fluorescence spectroscopy Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- FYBHCRQFSFYWPY-UHFFFAOYSA-N purmorphamine Chemical compound C1CCCCC1N1C2=NC(OC=3C4=CC=CC=C4C=CC=3)=NC(NC=3C=CC(=CC=3)N3CCOCC3)=C2N=C1 FYBHCRQFSFYWPY-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 101100400452 Caenorhabditis elegans map-2 gene Proteins 0.000 description 1
- 101100316741 Danio rerio slc18a3b gene Proteins 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 101000619910 Homo sapiens LIM/homeobox protein Lhx6 Proteins 0.000 description 1
- 101000619912 Homo sapiens LIM/homeobox protein Lhx8 Proteins 0.000 description 1
- 102100022098 LIM/homeobox protein Lhx6 Human genes 0.000 description 1
- 102100022136 LIM/homeobox protein Lhx8 Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101150088805 Slc18a3 gene Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100039452 Vesicular acetylcholine transporter Human genes 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000020339 forebrain development Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/195—Heregulin, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及hPSCs诱导分化制备的基底前脑胆碱能类器官及其制备方法,属于生物医学和发育生物技术领域。方法包括如下步骤:将hPSCs贴壁培养,增殖后消化制成拟胚体,在神经诱导培养液中悬浮培养分化,分化第1天,每天半换液进行培养,更换的培养液均为腹侧化因子SHH。分化第7天时进行贴壁培养,第10天时得到神经管样细胞结构。分化第16天将形成的神经管样细胞结构吹下,将管底细胞用NIM培养液悬浮培养,其中添加SHH和B27,第17天将自发形成球状神经前体细胞。分化第25天使用含有β‑NGF的NIM培养,在分化第45天获得包含大量胆碱能神经元的基底前脑胆碱能类器官。本发明体外模拟了基底前脑的发育,为多种医学实验提供了细胞模型。
Description
技术领域
本发明涉及一种hPSCs诱导分化制备的基底前脑胆碱能类器官及其制备方法,属于生物医学和发育生物技术领域。
背景技术
基底核团对正常的脑功能和行为至关重要。其中,基底前脑胆碱能神经元参与记忆、情感和奖励学习等高级认知功能的调节,并在唐氏综合中呈现出不同程度的损害。基底前脑胆碱能神经元投射系统在学习认知中发挥关键作用。然而由于伦理要求,人脑组织样本尤其是胚胎时期的脑组织,更是难以获取。目前对唐氏综合征研究主要为小鼠等模式动物,但由于模式动物与人类大脑之间的种属差异,使得仅用动物模型来研究人类神经系统疾病的局限性不可避免。
人脑是一个复杂的器官,包含多种细胞和组织类型,它们通过错综复杂的途径相互作用。神经病理条件往往是这些细胞类型之间复杂相互作用的结果。虽然在2D培养中,人类诱导多能干细胞分化为神经元有助于我们理解神经退行性疾病相关的发病机制,但这些系统只能模拟单个大脑区域,而不能完全捕获不同细胞类型之间的复杂相互作用。最近开发了一些大脑球状体或类器官方案,以便更好地建模神经结构和功能的复杂性,并为细胞的发育和成熟提供更真实的3D环境。
近年来,从hPSCs分化出来的人脑类器官被认为是研究人脑发育/发病机制的有效实验模型。hPSCs可在体外通过诱导,自发组织成被称为类器官(organoid)的多细胞器官样结构。人脑类器官可以在很大程度上概括离散的大脑区域的结构功能特性,为人脑发育和神经系统疾病提供了可研究的模型基础。已有研究通过单细胞测序对比分析了人类大脑细胞、人脑类器官细胞和猕猴等灵长类动物大脑细胞,发现人脑类器官与人类大脑具有高度相似性,从而证明了人脑类器官可作为模型研究人类大脑发育及神经系统疾病。
目前已经建立了产生多种特定区域的类脑器官,例如脑皮质,丘脑,下丘脑,中脑和脊髓,这有助于研究神经系统疾病的发病机制,例如小头畸形,自闭症和阿尔茨海默氏病。然而,目前仍无产生基底前脑胆碱能类器官的方法报道。在神经系统发育过程中,基底前脑发育起源于内侧神经节隆起(Medial ganglionic eminence, MGE)。其中,MGE可大量表达转录因子NKX2.1、LHX6、LHX8等,产生大量胆碱能神经元,成熟的胆碱能神经元则会表达标记物CHAT、VACHT等。因此,建立一种高效诱导hPSCs定向分化为基底前脑胆碱能类器官的方法尤为重要。
发明内容
发明目的:针对上述现有存在的问题和不足,本发明的目的是提供一种hPSCs诱导分化制备的基底前脑胆碱能类器官及其制备方法,找到了一种高效分化hPSCs至基底前脑胆碱能类器官的方法,体外模拟了基底前脑的发育过程,构建了神经疾病模型,为研究发病机制、分子机理、细胞筛药提供了细胞模型。
技术方案:为实现上述发明目的,本发明采用以下技术方案:
一种hPSCs诱导分化制备的基底前脑胆碱能类器官的制备方法,包括如下步骤:
步骤1:将hPSCs贴壁培养,增殖后消化制成拟胚体(embryonic body,EB),在神经诱导培养液中悬浮培养分化,此天记为第0天;
步骤2:分化第1天记为第1天,每天半换液进行培养,更换的培养液均为腹侧化因子SHH;
步骤3:分化第7天时进行贴壁培养,第10天时得到神经管样细胞结构;
步骤4:分化第16天将形成的神经管样细胞结构吹下,自然沉降,弃上清,将管底细胞用NIM培养液悬浮培养,其中添加体积比为1:50的SHH和B27,第17天将自发形成球状神经前体细胞;
步骤5:分化第25天使用含有β-NGF的NIM培养,在分化第45天获得包含大量胆碱能神经元的基底前脑胆碱能类器官。
进一步的,所述步骤1具体步骤为:将hPSCs贴壁培养于在4℃用基质胶Vitronectin提前一晚包被过的培养皿中,hPSCs在培养皿中增殖至60-80%密度时进行消化,置于37°C,5% CO2的孵箱中孵育1~7分钟,显微镜下观察到克隆边缘发亮,并微微卷起时,将Dispase吸除,用DMEM/F12轻洗一遍细胞,再用DMEM/F12轻轻将克隆吹下,一边吹一边将已吹下的克隆从液体中吸出转移至15ml离心管中,将离心管离心,800rpm,1min后吸弃上清,将管底的细胞转移至细胞培养瓶中悬浮培养,换上神经诱导培养液(Neural inductionmedium,NIM),将细胞制成EB,此时为细胞分化的第0天。
进一步的,所述提前一晚包被过的培养皿中培养液为Essential 8,由体积比为50:1的 Essential 8TM Basal Medium DMEM/F12(Ham)(1:1)与Essential 8TM Supplement(50X)配制而成;用1U/ml的Dispase进行消化,所述神经诱导培养液NIM为DMEM/F12培养基、NEAA和N2以体积比98:1:1配制而成。
进一步的,所述步骤2的腹侧化因子SHH浓度为250-1000ng/ml。
进一步的,所述步骤3具体步骤为:分化第7天时把EB从培养瓶吸出置于离心管中,待细胞自然沉降到管底后,吸走上清,用枪将拟胚体吸出,置于细胞培养皿中,每个培养皿中大约含40-50个EB,10小时后更换为加入SHH的神经诱导培养液。
进一步的,所述步骤3中所用的培养液为NIM和10%的 胎牛血清FBS混合液。
进一步的,所述步骤5所述的含有的β-NGF浓度为50ng/ml。
一种hPSCs诱导分化制备的基底前脑胆碱能类器官,其由权利要求1-7的所述的任一方法制得。
有益效果:与现有技术相比,本发明具有以下优点:这是一种新式的hPSCs诱导分化制备的基底前脑胆碱能类器官及其制备方法,在诱导分化第37天,可获得包含大量MGE神经祖细胞标记物NKX2.1(>90%)的基底前脑胆碱能类器官,分化第45天时可观察到较多胆碱能神经元标记物CHAT。分化第45天时,可得到大量CHAT阳性(>40%)的胆碱能神经元。
附图说明
图1是本发明的实验诱导流程示意图;
图2是本发明的实施例分化初期荧光结果示意图,
图中:a为分化第4天,b为分化第5天;
图3是本发明的实施例分化中期荧光实验结果示意图,
图中:c为分化12天,d为分化20天;
图4是本发明的实施例分化第37天的荧光实验结果示意图;
图5是本发明的实施例分化第45天的荧光实验结果示意图。
具体实施方式
下面结合附图和具体实施例,进一步阐明本发明,应理解这些实施例仅用于说明本发明而不用于限制本发明的范围,在阅读了本发明之后,本领域技术人员对本发明的各种等价形式的修改均落于本申请所附权利要求所限定的范围。
如图1所示,一种hPSCs诱导分化制备的基底前脑胆碱能类器官及其制备方法过程,下面用实施例来验证本发明的可实施性。
实施例:
本实施例步骤如下:
步骤1,将hPSCs贴壁培养,待增殖至60-80%密度时消化制成EB,在神经诱导培养液中悬浮培养,在神经诱导培养液中悬浮培养具体为:
将hPSCs贴壁培养于在4℃用基质胶Vitronectin提前一晚包被过的培养皿中;hPSCs所用培养液为Essential 8,由体积比为50:1的 Essential 8TM Basal MediumDMEM/F12(Ham)(1:1)与Essential 8TM Supplement (50X)配制而成;
hPSCs在培养皿中增殖至60-80%密度时用1ml Dispase(1Uml-1)进行消化,置于37°C,5% CO2的孵箱中孵育2分钟,显微镜下观察到克隆边缘发亮,并微微卷起时,将Dispase吸除;用DMEM/F12轻洗一遍细胞,再用DMEM/F12轻轻将克隆吹下,一边吹一边将已吹下的克隆从液体中吸出转移至15ml离心管中;将离心管离心,800rpm,1min后吸弃上清,将管底的细胞转移至细胞培养瓶中悬浮培养,换上神经诱导培养液(Neural inductionmedium, NIM),将细胞制成拟胚体,其中,神经诱导培养液NIM为DMEM/F12培养基,NEAA,N2以体积比98:1:1配制而成。
步骤2,在分化第1天加入腹侧化因子SHH的抑制剂,具体为:
分化第1天在神经诱导培养液中加入腹侧化因子SHH,浓度为250-1000ng/ml,分化第1天至分化第7天,每天半换液,7天之后,隔天半换液,更换的培养液均为加入SHH的神经诱导培养液,持续至分化第20天。
步骤3,在分化第7天进行贴壁,第10天得到神经管样细胞结构具体为:
分化第7天时把EB从培养瓶吸出置于离心管中,待细胞自然沉降到管底后,吸走上清,用枪将EB吸出,置于细胞培养皿中,每个培养皿中大约含40-50个EB,细胞培养液为1.5ml NIM+10% FBS(0.15ml);10小时后更换为加入SHH的神经诱导培养液。
步骤4,在分化第16天将形成的神经管样细胞结构吹下,第17天将形成球状神经前体细胞,具体为:
分化第16天,用1ml的枪将形成神经管样细胞结构吹下,转移至15ml离心管中自然沉降,弃上清,将管底细胞转移至细胞培养瓶中,培养液为加入SHH的神经诱导培养液,并在其中加入B27,体积比是1:50;分化第17天,细胞将自发形成基底前脑胆碱能类器官。
步骤5中,在分化第16天使用含有SHH信号激动剂purmorphamine的NIM继续培养,具体为:
分化第16天至第24天,使用含有1.5μM SHH信号激动剂purmorphamine的NIM继续培养,隔天半换液。
步骤6中,在分化第25天使用含有的β-NGF 的NIM培养,在分化第45天获得包含大量胆碱能神经元的基底前脑胆碱能类器官,具体为;
分化第25天及以后,使用含有的50ng/mlβ-NGF 的NIM继续培养,隔天半换液。
步骤7,在细胞分化的第30天,第60天分别用4%多聚甲醛固定2-4小时后,用Phosphate Buffered Saline (PBS)漂洗3次后用30%蔗糖脱水,4℃静置,直至类器官沉入离心管管底。之后,将类器官利用OCT包埋,并进行切片。将切片用PBS漂洗3次,每次5分钟,用0.2%Triton X-100破膜,10%驴血清室温封闭1小时后,用5%的驴血清和0.1%Triton的PBS稀释一抗,4℃冰箱过夜。次日,PBS漂洗3次,每次10分钟,用5%驴血清稀释的二抗,室温孵育1小时,随后继续以PBS漂洗3次,最后抗淬灭免疫荧光封片剂封片。Nikon正置显微镜或Zeiss激光共聚焦显微镜(Zeiss 700b)观察拍照。
图1显示了诱导hPSCs分化至基底前脑胆碱能类器官的流程示意图。图2中a所示,细胞传代后第四天于基质胶Vitronectin稳定贴壁。图2中b所示,分化5天后,形成有明显神经外胚层样结构的EB。图3中c所示,分化12天,EB贴壁后出现明显神经管样结构。图3中d所示,分化20天,形成包含祖细胞和神经元的基底前脑胆碱能类器官。标尺=250μm。
图4所示,在分化在诱导分化的第37天,基底前脑胆碱能类器官可大量表达MGE祖细胞标记物NKX2.1,标尺=100μm。图5显示,在分化在诱导分化的D45天,基底前脑胆碱能类器官可大量表达胆碱能神经元标记物CHAT,成熟神经元标记物Map2。标尺=100μm。
实验结果证实,本发明所述的诱导分化方法可构建包含大量胆碱能神经元的基底前脑胆碱能类器官。
Claims (8)
1.一种hPSCs诱导分化制备的基底前脑胆碱能类器官的制备方法,其特征在于:包括如下步骤:
步骤1:将hPSCs贴壁培养,增殖后消化制成拟胚体(embryonic body,EB),在神经诱导培养液中悬浮培养分化,此天记为第0天;
步骤2:分化第1天记为第1天,每天半换液进行培养,更换的培养液均为腹侧化因子SHH;
步骤3:分化第7天时进行贴壁培养,第10天时得到神经管样细胞结构;
步骤4:分化第16天将形成的神经管样细胞结构吹下,自然沉降,弃上清,将管底细胞用NIM培养液悬浮培养,其中添加体积比为1:50的SHH和B27,第17天将自发形成球状神经前体细胞;
步骤5:分化第25天使用含有β-NGF的NIM培养,在分化第45天获得包含大量胆碱能神经元的基底前脑胆碱能类器官。
2.根据权利要求1所述的hPSCs诱导分化制备的基底前脑胆碱能类器官的制备方法,其特征在于:所述步骤1具体步骤为:将hPSCs贴壁培养于在4℃用基质胶Vitronectin提前一晚包被过的培养皿中,hPSCs在培养皿中增殖至60-80%密度时进行消化,置于37°C,5% CO2的孵箱中孵育1~7分钟,显微镜下观察到克隆边缘发亮,并微微卷起时,将Dispase吸除,用DMEM/F12轻洗一遍细胞,再用DMEM/F12轻轻将克隆吹下,一边吹一边将已吹下的克隆从液体中吸出转移至15ml离心管中,将离心管离心,800rpm,1min后吸弃上清,将管底的细胞转移至细胞培养瓶中悬浮培养,换上神经诱导培养液(Neural induction medium,NIM),将细胞制成EB,此时为细胞分化的第0天。
3.根据权利要求2所述的hPSCs诱导分化制备的基底前脑胆碱能类器官的制备方法,其特征在于:所述提前一晚包被过的培养皿中培养液为Essential 8,由体积比为50:1的Essential 8TM Basal Medium DMEM/F12(Ham)(1:1)与Essential 8TM Supplement(50X)配制而成;用1U/ml的Dispase进行消化,所述神经诱导培养液NIM为DMEM/F12培养基、NEAA和N2以体积比98:1:1配制而成。
4.根据权利要求1所述的hPSCs诱导分化制备的基底前脑胆碱能类器官的制备方法,其特征在于:所述步骤2的腹侧化因子SHH浓度为250-1000ng/ml。
5.根据权利要求1所述的hPSCs诱导分化制备的基底前脑胆碱能类器官的制备方法,其特征在于:所述步骤3具体步骤为:分化第7天时把EB从培养瓶吸出置于离心管中,待细胞自然沉降到管底后,吸走上清,用枪将拟胚体吸出,置于细胞培养皿中,每个培养皿中大约含40-50个EB,10小时后更换为加入SHH的神经诱导培养液。
6.根据权利要求1所述的hPSCs诱导分化制备的基底前脑胆碱能类器官的制备方法,其特征在于:所述步骤3中所用的培养液为NIM和10%的 胎牛血清FBS混合液。
7.根据权利要求1所述的hPSCs诱导分化制备的基底前脑胆碱能类器官的制备方法,其特征在于:所述步骤5所述的含有的β-NGF浓度为50ng/ml。
8.一种hPSCs诱导分化制备的基底前脑胆碱能类器官,其特征在于:其由权利要求1-7的所述的任一方法制得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111369833.1A CN114058587A (zh) | 2021-11-18 | 2021-11-18 | hPSCs诱导分化制备的基底前脑胆碱能类器官及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111369833.1A CN114058587A (zh) | 2021-11-18 | 2021-11-18 | hPSCs诱导分化制备的基底前脑胆碱能类器官及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114058587A true CN114058587A (zh) | 2022-02-18 |
Family
ID=80278084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111369833.1A Pending CN114058587A (zh) | 2021-11-18 | 2021-11-18 | hPSCs诱导分化制备的基底前脑胆碱能类器官及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114058587A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114657127A (zh) * | 2022-02-28 | 2022-06-24 | 武汉大学 | 一种大脑类器官模型及其制备方法与应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120040393A1 (en) * | 2010-08-12 | 2012-02-16 | Su-Chun Zhang | Directed Differentiation of Primate Pluripotent Stem Cells Into Functional Basal Forebrain Cholinergic Neurons (BFCNs) and Medium Spiny Gabaergic Projection Neurons |
CN103305458A (zh) * | 2012-03-06 | 2013-09-18 | 中国科学院上海生命科学研究院 | 从多潜能干细胞诱导胆碱能神经元的方法 |
CN105969733A (zh) * | 2016-05-09 | 2016-09-28 | 南京医科大学 | 诱导分化hPSCs为谷氨酰胺能神经元的方法 |
US20170266235A1 (en) * | 2014-08-25 | 2017-09-21 | Korea Research Institute Of Bioscience And Biotechnology | Method for producing cholinergic neural cells |
-
2021
- 2021-11-18 CN CN202111369833.1A patent/CN114058587A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120040393A1 (en) * | 2010-08-12 | 2012-02-16 | Su-Chun Zhang | Directed Differentiation of Primate Pluripotent Stem Cells Into Functional Basal Forebrain Cholinergic Neurons (BFCNs) and Medium Spiny Gabaergic Projection Neurons |
CN103305458A (zh) * | 2012-03-06 | 2013-09-18 | 中国科学院上海生命科学研究院 | 从多潜能干细胞诱导胆碱能神经元的方法 |
US20170266235A1 (en) * | 2014-08-25 | 2017-09-21 | Korea Research Institute Of Bioscience And Biotechnology | Method for producing cholinergic neural cells |
CN105969733A (zh) * | 2016-05-09 | 2016-09-28 | 南京医科大学 | 诱导分化hPSCs为谷氨酰胺能神经元的方法 |
Non-Patent Citations (1)
Title |
---|
HU YAO ET AL.,: ""Directed differentiation of basal forebrain cholinergic neurons fromhuman pluripotent stem cells"", 《JOURNAL OF NEUROSCIENCE METHODS》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114657127A (zh) * | 2022-02-28 | 2022-06-24 | 武汉大学 | 一种大脑类器官模型及其制备方法与应用 |
WO2023160688A1 (zh) * | 2022-02-28 | 2023-08-31 | 武汉大学 | 一种大脑类器官模型及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2950559C (en) | Culture method and cell cluster | |
RU2467066C2 (ru) | Способ конструирования массы миокардиальных клеток и применение массы миокардиальных клеток | |
US10913929B2 (en) | Method of differentiating stem cells | |
Sargent et al. | Cardiomyogenic differentiation of embryoid bodies is promoted by rotary orbital suspension culture | |
US9708582B2 (en) | Method of differentiating stem cells | |
Soong et al. | Cardiac differentiation of human embryonic stem cells and their assembly into engineered heart muscle | |
Giacomelli et al. | Co‐differentiation of human pluripotent stem cells‐derived cardiomyocytes and endothelial cells from cardiac mesoderm provides a three‐dimensional model of cardiac microtissue | |
US20060281136A1 (en) | Preparation of endodermal stem cells | |
Xu | Differentiation and enrichment of cardiomyocytes from human pluripotent stem cells | |
CN114149971A (zh) | 用hPSCs诱导分化得到中脑类器官的方法及中脑类器官 | |
CN113249310A (zh) | 一种拓展性多能干细胞诱导分化为心肌细胞的方法及应用 | |
US20170335286A1 (en) | Methods for maintaining and expanding mesenchymal stem cells on extracellular matrix coated microcarriers | |
CN114058587A (zh) | hPSCs诱导分化制备的基底前脑胆碱能类器官及其制备方法 | |
CN112852709B (zh) | 小鼠肺类器官培养方法 | |
JP6218152B2 (ja) | 内耳細胞誘導方法 | |
US20090221022A1 (en) | Three Dimensional Cell Culture | |
CN114107206A (zh) | 基于hPSCs诱导分化得到的纹状体类器官及hPSCs诱导分化方法 | |
Van Vranken et al. | The differentiation of distal lung epithelium from embryonic stem cells | |
EP1743936A1 (en) | Mesenchymal stem cell precursor | |
Lü et al. | Bioreactor cultivation enhances NTEB formation and differentiation of NTES cells into cardiomyocytes | |
US20150159133A1 (en) | Method of in vitro differentiation of motor neuron progenitors (mnps) from human induced pluripotent stem cells and cryopreservation of mnps | |
CN110592007A (zh) | 一种间充质干细胞及其制备方法和应用 | |
Gao et al. | Prospective identification and culture of rat enteric neural stem cells (ENSCs) | |
Sukhinich et al. | Cerebral organoids: a model of brain development | |
WO2013130075A1 (en) | Culture system for stem cell propagation and neural and oligodendrocyte specification in microgravity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220218 |